| Ticker Details |
Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company. The company operates in one reportable segment: the research, manufacture, and distribution of patient-specific, used in the treatment of specific diseases.
|
| IPO Date: |
November 25, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.93B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.57 | 2.53%
|
| Avg Daily Range (30 D): |
$0.80 | 2.15%
|
| Avg Daily Range (90 D): |
$0.82 | 2.19%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.46M |
| Avg Daily Volume (30 D): |
.34M |
| Avg Daily Volume (90 D): |
.44M |
| Trade Size |
| Avg Trade Size (Sh.): |
97 |
| Avg Trade Size (Sh.) (30 D): |
47 |
| Avg Trade Size (Sh.) (90 D): |
48 |
| Institutional Trades |
| Total Institutional Trades: |
3,054 |
| Avg Institutional Trade: |
$2.5M |
| Avg Institutional Trade (30 D): |
$2.39M |
| Avg Institutional Trade (90 D): |
$2.45M |
| Avg Institutional Trade Volume: |
.08M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.98M |
| Avg Closing Trade (30 D): |
$3.22M |
| Avg Closing Trade (90 D): |
$3.63M |
| Avg Closing Volume: |
90.04K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$.1
|
$-.01
|
$-.23
|
|
Diluted EPS
|
$.1
|
$-.01
|
$-.23
|
|
Revenue
|
$67.5M
|
$63.24M
|
$52.6M
|
|
Gross Profit
|
$49.59M
|
$46.61M
|
$36.27M
|
|
Net Income / Loss
|
$5.07M
|
$-.55M
|
$-11.25M
|
|
Operating Income / Loss
|
$3.45M
|
$-2.03M
|
$-12.79M
|
|
Cost of Revenue
|
$17.92M
|
$16.63M
|
$16.33M
|
|
Net Cash Flow
|
$19.87M
|
$.83M
|
$-5.34M
|
|
PE Ratio
|
382.50
|
|
|
| Splits |
|
Oct 16, 2013
|
1:20
|
|
Feb 18, 2010
|
1:8
|
|
|
|
